Virus-based vectors for human vaccine applications

Drug Discovery Today

Volumn 7, Issue 13, 2002, Pages 719-727

  Polo, John M ^a   Dubensky, Thomas W ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b CERUS CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIGEN; CANCER VACCINE; DNA VACCINE; GLYCOPROTEIN GP 100; INACTIVATED VIRUS VACCINE; LIVE VACCINE; MELANOMA ANTIGEN; PLASMID VECTOR; POLIOMYELITIS VACCINE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 2; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; VACCINE; VIRUS VECTOR;

ALPHA VIRUS; ANTIGEN PRESENTATION; CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CHORDOPOXVIRINAE; CLINICAL TRIAL; DNA VECTOR; DRUG EFFICACY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; GENETIC CODE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOSTIMULATION; INFECTION; INFECTION RISK; MALIGNANT NEOPLASTIC DISEASE; METHODOLOGY; NONHUMAN; POLIOMYELITIS VIRUS; POXVIRUS; REPLICON; REVIEW; RHABDOVIRUS; VACCINATION; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; GENE VECTOR; GENETICS; VIRUS;

GENETIC VECTORS; HUMAN; POLIOVIRUS; VACCINES; VIRUSES; HUMANS;

EID: 0036629242     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(02)02324-3     Document Type: Review

References (69)

1. Vaccines, coming of age after 200 years
2. Vaccines in historic evolution and perspective: A narrative of vaccine discoveries
3. Cancer vaccines
4. Reverse vaccinology, a genome-based approach to vaccine development
5. Gene expression microarrays: A 21st century tool for directed vaccine design
6. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety
7. Applications of pox virus vectors to vaccination: An update
8. Vaccinia virus: A selectable eukaryotic cloning and expression vector
9. Construction of poxviruses as cloning vectors: Insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus
10. Introduction of foreign DNA into the vaccinia virus genome by in vitro ligation: Recombination-independent selectable cloning vectors
11. Construction of chimeric vaccinia viruses by molecular cloning and packaging
12. Nonreplicating vaccinia vector efficiently expresses recombinant genes
13. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence
14. NYVAC: A highly attenuated strain of vaccinia virus
15. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein
16. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria
17. Induction of Japanese encephalitis virus-specific cytotoxic T lymphocytes in humans by poxvirus-based JE vaccine candidates
18. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus-poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans
19. Recombinant fowlpox virus inducing protective immunity in non-avian species
20. Efficacy studies on a canarypox-rabies recombinant virus
21. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: An alternative poxvirus vector system
22. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: A Phase 2 study in higher- and lower-risk volunteers
23. Adenovirus vectors for human gene therapy
24. Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics
25. Interactions between adenovirus proteins and the p53 pathway: The development of ONYX-015
26. An enhanced system for construction of adenoviral vectors by the two-plasmid rescue method
27. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses
28. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: Results of a Phase I clinical trial
29. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens
30. Development of a preventive vaccine for Ebola virus infection in primates
31. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
32. Generation of helper-dependent adenoviral vectors by homologous recombination
33. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors
34. Selectively replicating adenoviruses for oncolytic therapy
35. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
36. Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy
37. Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the E3B region
38. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells
39. The alphaviruses: Gene expression, replication, and evolution
40. Alphavirus vectors for gene expression and vaccines
41. Sindbis virus: An efficient, broad host range vector for gene expression in animal cells
42. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon
43. Sindbis virus DNA-based expression vectors: Utility for in vitro and in vivo gene transfer
44. A plasmid-based self-amplifying Sindbis virus vector
45. DNA immunization against herpes simplex virus: Enhanced efficacy using a Sindbis virus-based vector
46. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors
47. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines
48. Self-replicating Semliki Forest virus RNA as recombinant vaccine
49. Sindbis virus expression vectors: Packaging of RNA replicons by using defective helper RNAs
50. Sindbis virus replicons and Sindbis virus: Assembly of chimeras and of particles deficient in virus RNA
51. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: Expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo
52. Stable alphavirus packaging cell lines for Sindbis virus- and Semliki Forest virus-derived vectors
53. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis
54. Infection of human dendritic cells by a Sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein
55. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice
56. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates
57. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles
58. Expression of human immunodeficiency virus type 1 (HIV-1) gag, pol and env proteins from chimeric HIV-1- poliovirus minireplicons
59. Encapsidation of genetically engineered poliovirus minireplicons which express human immunodeficiency virus type 1 gag and pol proteins upon infection
60. Engineering poliovirus as a vaccine vector for the expression of diverse antigens
61. Attenuated poliovirus strain as a live vector: Expression of regions of rotavirus outer capsid protein VP7 by using recombinant Sabin 3 viruses
62. Protection against Simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors
63. Expression of foreign proteins by poliovirus polyprotein fusion: Analysis of genetic stability reveals rapid deletions and formation of cardioviruslike open reading frames
64. Infectious rabies viruses from cloned cDNAs
65. Highly stable expression of a foreign gene from rabies virus vectors
66. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus
67. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge
68. Recombinant rabies virus as potential live-viral vaccines for HIV-1
69. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1